By Matt Grossman


AbbVie Inc. said Friday it received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding its Venclyxto treatment for people with acute myeloid leukemia.

The opinion covers the use of Venclyxto combined with hypomethylating agents to treat adults with newly diagnosed AML who are ineligible for chemotherapy. The body's opinion is a scientific recommendation that will feed into the European Commission's decision on whether to grant the therapy marketing authorization.

The EC is expected to give its final decision on the therapy in the first half of this year, AbbVie said.

AML is the most common type of acute leukemia, with about 160,000 people in the world currently living with the disease, North Chicago, Ill.-based AbbVie said.


Write to Matt Grossman at


(END) Dow Jones Newswires

April 23, 2021 08:45 ET (12:45 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.